Product stability studies for rigosertib, a Phase 3 clinical stage product in development for Myelodysplastic Syndromes (MDS) Discovery of a novel kinase inhibitor, ON 150030, a Type 1 inhibitor of FLT3 and Src for relapsed and refractory Acute Myeloid Leukemia (AML) NEWTOWN, Pa. , Feb.
NEWTOWN, Pa. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),
NEWTOWN, Pa. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),
NEWTOWN, Pa. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it will present an abstract relating to the mechanism of action
Independent Data Monitoring Committee (DMC) recommends continuation of INSPIRE trial with trial expansion per adaptive design based on interim analysis results for overall survival Trial Executive Committee unanimously agreed to continue the Intent To Treat (ITT) study population and increase
Agreement related to study of rigosertib in pediatric RASopathies Clinical trial in pediatric patients to be conducted by the National Cancer Institute RASopathies are orphan diseases believed to be caused by molecular defects in the RAS pathway NEWTOWN, Pa. , Jan.
NEWTOWN, Pa. , Dec. 28, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present at Biotech Showcase
HanX to commercialize in Greater China : Onconova retains rights in rest of the world HanX will fund studies towards Investigational New Drug (IND) applications in both the US and China Agreement includes licensing fee, customary milestone payments and royalties on sales NEWTOWN, Pa. , Dec.
Oral rigosertib as a single agent demonstrates activity in a Phase 2 trial for lower-risk MDS 32% of 62 evaluable patients, and 44% of patients receiving optimal dosing, achieved transfusion independence New data on the molecular basis of the combination therapy with rigosertib and azacitidine in
NEWTOWN, Pa. , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present at the LD Micro
